Juniper Biosciences Appoints Dr. Jason S. Lewis as Chair of Scientific Advisory Board
Juniper Biosciences has established a Scientific Advisory Board (SAB) and appointed Dr. Jason S. Lewis as its Chair. Dr. Lewis, an expert in molecular imaging and radiochemistry, will guide the company’s precision oncology pipeline, including its lead asset JBS-003, currently in Phase 3 trials. His leadership aims to align Juniper’s clinical programs with the needs of the nuclear medicine ecosystem.
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) — Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment of Jason S. Lewis, Ph.D., as its inaugural Chair. Dr. Lewis, a world-renowned leader in molecular imaging and radiochemistry, will lead a multidisciplinary group of experts to guide the clinical and strategic development of Juniper’s precision oncology pipeline.